Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

NCT03730129 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Secondary Immune Deficiency Disorder

Interventions

DRUG: Hizentra

Sponsor

Rochester General Hospital